STERIS' (STE) fourth-quarter performance in AST is dented by a decline in capital equipment revenues. The contraction of margins is concerning.
Charles River's (CRL) Manufacturing and RMS business segments report organic revenue growth.
Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences' (EXAS) first-quarter top line.